Journal article
FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition
The Journal of clinical investigation, Vol.131(10), e145546
05/17/2021
DOI: 10.1172/JCI145546
PMID: 33822771
Abstract
The protein kinases IKK-epsilon and TBK1 are activated in liver and fat in mouse models of obesity. We have previously demonstrated that treatment with the IKK-epsilon/TBK1 inhibitor, amlexanox, produces weight loss and relieves insulin resistance in obese animals and patients. While amlexanox treatment caused a transient reduction in food intake, long-term weight loss was attributable to increased energy expenditure via FGF21-dependent beiging of WAT. Amlexanox increased FGF21 synthesis and secretion in several tissues. Interestingly, while hepatic secretion determined circulating levels, it was dispensable for regulating energy expenditure. In contrast, adipocyte-secreted FGF21 may have acted as an autocrine factor that leads to adipose tissue browning and weight loss in obese mice. Moreover, increased energy expenditure was an important determinant of improved insulin sensitivity by amlexanox. Conversely, the immediate reductions in fasting blood glucose observed with acute amlexanox treatment were mediated by suppression of hepatic glucose production via the activation of STAT3 by adipocyte-secreted IL-6. These findings demonstrate that amlexanox improved metabolic health via FGF21 action in adipocytes to increase energy expenditure via WAT beiging, and an endocrine role of adipocyte-derived IL-6 to decrease gluconeogenesis via hepatic STAT3 activation, thereby producing a coordinated improvement in metabolic parameters.
Details
- Title: Subtitle
- FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition
- Creators
- Shannon M Reilly - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaMohammad Abu-Odeh - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaMagdalene Ameka - Department of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, United States of AmericaJulia H DeLuca - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaMeghan C Naber - Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, United States of AmericaBenyamin Dadpey - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaNima Ebadat - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaAndrew V Gomez - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaXiaoling Peng - Life Sciences Institute, The University of Michigan, Ann Arbor, United States of AmericaBreAnne Poirier - Life Sciences Institute, The University of Michigan, Ann Arbor, United States of AmericaElyse Walk - Department of Medicine, University of California, San Diego, La Jolla, United States of AmericaMatthew J Potthoff - Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, United States of AmericaAlan R Saltiel - Department of Medicine, University of California, San Diego, La Jolla, United States of America
- Resource Type
- Journal article
- Publication Details
- The Journal of clinical investigation, Vol.131(10), e145546
- Publisher
- American Society for Clinical Investigation
- DOI
- 10.1172/JCI145546
- PMID
- 33822771
- ISSN
- 0021-9738
- eISSN
- 1558-8238
- Grant note
- DOI: 10.13039/100000002, name: US National Institutes of Health, award: F32DK09685101, 1K01DK105075, R03DK118195, R01DK106104, P30 DK063491, R01DK117551, R01DK125820, R01DK076906; DOI: 10.13039/100000041, name: American Diabetes Association, award: 1-19-JDF-012, 1-19-PDF-177
- Language
- English
- Electronic publication date
- 04/06/2021
- Date published
- 05/17/2021
- Academic Unit
- Iowa Neuroscience Institute; Neuroscience and Pharmacology
- Record Identifier
- 9984071947302771
Metrics
11 Record Views